---
category: news
title: "Will Gilead price its coronavirus drug for public good or company profit?"
excerpt: "Gilead Sciences Inc faces a new dilemma in deciding how much it should profit from the only treatment so far proven to help patients infected with the novel coronavirus."
publishedDateTime: 2020-05-06T17:15:00Z
webUrl: "https://www.reuters.com/article/us-health-coronavirus-gilead-pricing-idUSKBN22I2NM"
ampWebUrl: "https://mobile.reuters.com/article/amp/idUSKBN22I2NM"
cdnAmpWebUrl: "https://mobile-reuters-com.cdn.ampproject.org/c/s/mobile.reuters.com/article/amp/idUSKBN22I2NM"
type: article
quality: 104
heat: 104
published: true

provider:
  name: Reuters
  domain: reuters.com
  images:
    - url: "https://insideout.app/coronavirus/assets/images/organizations/reuters.com-50x50.jpg"
      width: 50
      height: 50

topics:
  - Treatment
  - Coronavirus

images:
  - url: "https://s1.reutersmedia.net/resources/r/?m=02&d=20200506&t=2&i=1517696900&w=&fh=545px&fw=&ll=&pl=&sq=&r=LYNXMPEG451Q2"
    width: 752
    height: 545
    title: "Will Gilead price its coronavirus drug for public good or company profit?"

secured: "mxqvsU98a+/xcTV1F86QhkE7p/cgK5Wuv7EU+bKxLQrQ1u/vYmIjn/6fCec6zY53+yrtlLsXuPZEq8LWRaZqL8Jb6DfnELIFK2xrynCyMNaDfocCtXNnG7S7E7J2nwmAHoHNzZHT9s4Rrk7r+l74tMPxQhSAfTUv0rsn9wePsmX3oAlNNNtj6SS6mtiJyGXLOFqEiR+VOwsXyt2M81bjf00LwRVZ6e8tfv6R/sm0vSBQ6x2aJL/b/9kHwjYnp+14KgXPcIFJQ1QKym1LvC58rv3W0pfDBLq3MJK//CYS4hCtOyhOJ5YAqk5Qr3SFSbaYi37E5sWOmsIIGtJeA6vW4mnlppeFvukYwIm85L07z6DKAL/8aDH1OQ+EGVvmrCLnygRkzZ479eCwm6E4HYO11TBQIEhMRiDwYHNftwQfLgRYJ4IKO/KpOac/ir1Hg7kdfJBe6n1hvFnndkDnF+48pyvSpjYGLwxPaneP9JHsxpY=;1g1Y1cRaZXBxnXfugg3m3g=="
---

